Development and in vitro evaluation of solid dispersions of Candesartan cilexetil was written by Kumar, Uppuluru Ashok;Suresh, Gande. And the article was included in Asian Journal of Pharmaceutical and Clinical Research in 2019.Quality Control of 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate This article mentions the following:
The main objective of the present study is the systematic development of solid dispersions of Candesartan cilexetil by solvent evaporation method to enhance the solubility and bioavailability. In the present study, 18 formulations of SD were prepared with 1:1 and 1:3 ratios of drug: Carrier and with and without surfactant. There was a significant improvement in the rate of drug release from all 20 SD and the formulation (SD16) comprising Candesartan: Containing Soluplus (1:3 ratio of drug: Soluplus with 2% sodium lauryl sulfate as a surfactant) by a solvent evaporation process. Final optimized design SD16 contained maximum drug content of 99.08%. In in vitro dissolution studies, it shows greater dissolution rate, i.e., 99.7 ± 4.2% associated through addnl. designs and pure drug. The drug was compatible with all the excipients as per the Fourier transform IR spectroscopy. From powder X-ray diffraction and by (scanning electron microscope) studies, it was evident that crystalline form of Candesartan has been converted into amorphous form within SD design. From these studies, we can accomplish SD are one of the greatest favorable formulation for Candesartan cilexetil for enhancing the solubility and bioavailability of poorly water-soluble drugs in the effective group of hypertension and other cardiac problems. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Quality Control of 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate).
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Quality Control of 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem